Partnerships Grifols (exclusive commercialization license, Europe/UK/Turkey/Middle East/North Africa/Russia-CIS); Kissei (exclusive license and supply, approved in Korea Jan 2025); Medison (Canada and Israel, chronic ITP); Knight Therapeutics International (Latin America)
Indications
chronic immune thrombocytopenia (ITP)(Approved)
Status note First FDA-approved product; only approved oral SYK inhibitor for adult chronic ITP patients with insufficient response to prior treatment. Commercialized ex-US through multiple licensees.
olutasidenib
Phase 2 · ActiveModality: oral small molecule (IDH1 inhibitor)
Target IDH1
Partnerships MD Anderson Cancer Center and CONNECT (development collaborations for IDH1-mutation disease areas); Kissei (exclusive development/commercialization rights in Kissei territory, Sept 2024)
Indications
relapsed or refractory acute myeloid leukemia (AML) with IDH1 mutation(Approved)
glioma(Phase 2)
Status note Second FDA-approved product (REZLIDHIA) for adult R/R AML with susceptible IDH1 mutation. In Jan 2024 Rigel announced a collaboration with CONNECT to evaluate olutasidenib in glioma via the molecularly guided Phase 2 umbrella TarGet study (first patient enrolled Oct 2025).
R289
Phase 1 · ActiveModality: small molecule inhibitor
Status note Dual IRAK1/4 inhibitor in open-label Phase 1b study evaluating safety, tolerability and preliminary efficacy in patients with lower-risk MDS relapsed, refractory or resistant to prior therapy.
Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.